Skip to main content
. 2020 Aug 31;10:14289. doi: 10.1038/s41598-020-71225-1

Figure 2.

Figure 2

Neutralisation of EBOV (Mayinga) GP pseudotyped (a) HIV-1, n = 2, and (b) VSV, n = 4, by human anti-EBOV GP mAb, KZ52. Percentage infectivity was calculated relative to pseudotyped virus only controls. Data are shown for mean with log (inhibitor) vs. normalised response curves. Error bars are 1 standard error above and below the mean. Dotted lines represent 50% infectivity.